Gerresheimer (ETR:GXI) received a €68.00 ($79.07) target price from Commerzbank in a research report issued to clients and investors on Thursday. The firm currently has a “neutral” rating on the stock. Commerzbank’s target price indicates a potential downside of 5.95% from the stock’s current price.
Other equities research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. set a €74.00 ($86.05) target price on shares of Gerresheimer and gave the stock a “neutral” rating in a research report on Tuesday, April 10th. Credit Suisse Group set a €72.00 ($83.72) target price on shares of Gerresheimer and gave the stock a “buy” rating in a research report on Tuesday, April 10th. Berenberg Bank set a €78.00 ($90.70) target price on shares of Gerresheimer and gave the stock a “buy” rating in a research report on Thursday, April 12th. Deutsche Bank reiterated a “neutral” rating on shares of Gerresheimer in a research report on Friday, April 13th. Finally, Kepler Capital Markets set a €65.00 ($75.58) target price on shares of Gerresheimer and gave the stock a “sell” rating in a research report on Thursday, April 12th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of €69.29 ($80.57).
GXI stock opened at €72.30 ($84.07) on Thursday. Gerresheimer has a 12-month low of €59.97 ($69.73) and a 12-month high of €78.25 ($90.99).
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.